Optain discloses $13 million to expand US retinal screening
The newly disclosed financing amount supports expansion of robotic retinal imaging across US health systems.

Optain has put a number on the financing behind its US expansion.
What happened
On 13 November, CEO Jeff Dunkel disclosed $13 million raised to expand robotic retinal imaging across US health systems. The company first announced the financing without an amount on 10 November. Investors include Morningside, Insight Partners, the UniQuest Extension Fund and health-system investors.
Why it matters
Optain's US service combines a robotic retinal camera, imaging software and remote specialist assessment. Bringing screening into routine care visits can reduce the practical work involved in arranging a separate appointment.
The bigger picture
Scaling a healthcare product involves clinical workflows and enterprise deployment alongside the device itself. This financing supports the work of introducing screening across more sites and health-system networks.
